Summary

The compounding chemotherapy market was valued at $5,267.03 million in 2024 and is estimated to reach $9,826.7 million by 2034, exhibiting a CAGR of 6.4% from 2025 to 2034.Compounding chemotherapy involves the specialized preparation of customized chemotherapy medications by trained pharmacists, typically in a compounding or hospital pharmacy. This process includes the precise mixing, modifying, or combining of chemotherapy drugs to address the specific needs of individual patients.
Compounded formulations are often necessary when commercial products are unavailable, when a tailored dosage or drug combination is required, or when patients have allergies to ingredients in standard treatments. By combining drugs with different mechanisms of action, compounded chemotherapy can target cancer cells at various stages of their growth cycle, potentially improving therapeutic outcomes.
The compounding chemotherapy market is experiencing robust growth, driven by a rising global cancer burden, increasing demand for personalized medicine, and the need for customized drug formulations. According to the World Health Organization (WHO), over 35 million new cancer cases are projected by 2050—representing a 77% increase from the 20 million cases reported in 2022. This surge has significantly heightened the demand for comprehensive and effective cancer treatments, contributing to the growing adoption of compounded chemotherapy.
Compounding chemotherapy, which typically involves combining two or more chemotherapeutic agents, is increasingly favored for its synergistic effects in targeting cancer cells, reducing drug resistance, and improving clinical outcomes. The expansion of personalized medicine and advancements in genomics have further supported the development of individualized treatment regimens based on specific tumor profiles, bolstering market demand.
Another key market driver is the increasing investment in research and development by pharmaceutical companies and academic institutions, aimed at creating novel compound formulations with enhanced safety and efficacy. Regulatory bodies are also contributing to market growth by offering fast-track approvals and incentives for innovative and breakthrough therapies.
Growing awareness among healthcare professionals and patients regarding the advantages of combination therapies—along with improved diagnostic technologies—has accelerated market penetration, particularly in developed regions such as North America and Europe. Additionally, the expansion of compounding chemotherapy in pediatric oncology and the emergence of outpatient and home-based cancer treatment options are creating new growth opportunities, particularly for compact and user-friendly compounding systems.
However, clinical challenges remain. The risk of cumulative toxicity and potential drug interactions necessitates close patient monitoring and individualized dosage adjustments, which can limit broader adoption.
Key players operating in the market have adopted product launch, acquisition, and partnership as their key strategies to expand their product portfolio. For example, the SmartCompounders robotic chemo-automation system by Simplivia is engineered to enhance the safety, accuracy, and efficiency of cytotoxic drug preparation. A standout feature of this system is its precision-driven gravimetric control, which employs ten distinct load cells to measure medication dosing in real time post-injection, ensuring total accuracy and reliability. This gravimetric approach minimizes dosing errors and enhances patient safety.
Segment Review:
The compounding chemotherapy market is segmented into dose type, compounding type, delivery method, sterility, technology, and region. By dose type, the market is segregated into chemotherapeutic and non-chemotherapeutic. By compounding type, the market is classified into pharmaceutical ingredient alteration, currently unavailable pharmaceutical manufacturing, and pharmaceutical dosage alteration. By delivery method, the market is segmented into gravimetric automated compounding devices, and volumetric automated compounding devices. By sterility, the market is segmented into sterile and non-sterile. By technology, the market is segmented into with robotic arm and without robotic arm. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global compounding chemotherapy market are ATS Corporation, Grifols, S.A., EQUASHIELD, Dedalus S.p.A., ARxIUM, Omnicell Inc., Kapsam Health Products, Simplivia, Biovalley Group S.p.A., and Loccioni.
Key Benefits for Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding chemotherapy market analysis from 2024 to 2034 to identify the prevailing compounding chemotherapy market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the compounding chemotherapy market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global compounding chemotherapy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Average Selling Price Analysis / Price Point Analysis
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Technology
● With Robotic arm
● Without Robotic Arm
By Dose type
● Non-chemotherapeutic
● Chemotherapeutic
By Compounding Type
● Pharmaceutical Ingredient Alteration
● Currently Unavailable Pharmaceutical Manufacturing
● Pharmaceutical Dosage Alteration
By Delivery method
● Gravimetric automated Compounding Device
● Volumetric Automated Compounding Device
By Sterility
● Sterile
● Non-sterile
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Grifols, S.A.
○ EQUASHIELD
○ ARxIUM
○ Omnicell Inc.
○ Kapsam Health Products
○ Biovalley Group S.p.A.
○ Loccioni
○ ATS Corporation
○ Dedalus S.p.A.
○ Simplivia

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in global cancer incidence
3.4.1.2. Shortage of commercially available chemotherapy drugs
3.4.1.3. The shift toward personalized medicine
3.4.2. Restraints
3.4.2.1. Shortage of trained personnel
3.4.3. Opportunities
3.4.3.1. Advancements in compounding technologies
CHAPTER 4: COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapeutic
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Non-chemotherapeutic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical Ingredient Alteration
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Currently Unavailable Pharmaceutical Manufacturing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Pharmaceutical Dosage Alteration
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD
6.1. Overview
6.1.1. Market size and forecast
6.2. Gravimetric automated Compounding Device
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Volumetric Automated Compounding Device
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY
7.1. Overview
7.1.1. Market size and forecast
7.2. Sterile
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Non-sterile
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY
8.1. Overview
8.1.1. Market size and forecast
8.2. With Robotic arm
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by region
8.2.3. Market share analysis by country
8.3. Without Robotic Arm
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by region
8.3.3. Market share analysis by country
CHAPTER 9: COMPOUNDING CHEMOTHERAPY MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast By Region
9.2. North America
9.2.1. Key market trends, growth factors and opportunities
9.2.2. Market size and forecast, by Dose type
9.2.3. Market size and forecast, by Compounding Type
9.2.4. Market size and forecast, by Delivery method
9.2.5. Market size and forecast, by Sterility
9.2.6. Market size and forecast, by Technology
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. Market size and forecast, by Dose type
9.2.7.1.2. Market size and forecast, by Compounding Type
9.2.7.1.3. Market size and forecast, by Delivery method
9.2.7.1.4. Market size and forecast, by Sterility
9.2.7.1.5. Market size and forecast, by Technology
9.2.7.2. Canada
9.2.7.2.1. Market size and forecast, by Dose type
9.2.7.2.2. Market size and forecast, by Compounding Type
9.2.7.2.3. Market size and forecast, by Delivery method
9.2.7.2.4. Market size and forecast, by Sterility
9.2.7.2.5. Market size and forecast, by Technology
9.2.7.3. Mexico
9.2.7.3.1. Market size and forecast, by Dose type
9.2.7.3.2. Market size and forecast, by Compounding Type
9.2.7.3.3. Market size and forecast, by Delivery method
9.2.7.3.4. Market size and forecast, by Sterility
9.2.7.3.5. Market size and forecast, by Technology
9.3. Europe
9.3.1. Key market trends, growth factors and opportunities
9.3.2. Market size and forecast, by Dose type
9.3.3. Market size and forecast, by Compounding Type
9.3.4. Market size and forecast, by Delivery method
9.3.5. Market size and forecast, by Sterility
9.3.6. Market size and forecast, by Technology
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Market size and forecast, by Dose type
9.3.7.1.2. Market size and forecast, by Compounding Type
9.3.7.1.3. Market size and forecast, by Delivery method
9.3.7.1.4. Market size and forecast, by Sterility
9.3.7.1.5. Market size and forecast, by Technology
9.3.7.2. France
9.3.7.2.1. Market size and forecast, by Dose type
9.3.7.2.2. Market size and forecast, by Compounding Type
9.3.7.2.3. Market size and forecast, by Delivery method
9.3.7.2.4. Market size and forecast, by Sterility
9.3.7.2.5. Market size and forecast, by Technology
9.3.7.3. UK
9.3.7.3.1. Market size and forecast, by Dose type
9.3.7.3.2. Market size and forecast, by Compounding Type
9.3.7.3.3. Market size and forecast, by Delivery method
9.3.7.3.4. Market size and forecast, by Sterility
9.3.7.3.5. Market size and forecast, by Technology
9.3.7.4. Italy
9.3.7.4.1. Market size and forecast, by Dose type
9.3.7.4.2. Market size and forecast, by Compounding Type
9.3.7.4.3. Market size and forecast, by Delivery method
9.3.7.4.4. Market size and forecast, by Sterility
9.3.7.4.5. Market size and forecast, by Technology
9.3.7.5. Spain
9.3.7.5.1. Market size and forecast, by Dose type
9.3.7.5.2. Market size and forecast, by Compounding Type
9.3.7.5.3. Market size and forecast, by Delivery method
9.3.7.5.4. Market size and forecast, by Sterility
9.3.7.5.5. Market size and forecast, by Technology
9.3.7.6. Rest of Europe
9.3.7.6.1. Market size and forecast, by Dose type
9.3.7.6.2. Market size and forecast, by Compounding Type
9.3.7.6.3. Market size and forecast, by Delivery method
9.3.7.6.4. Market size and forecast, by Sterility
9.3.7.6.5. Market size and forecast, by Technology
9.4. Asia-Pacific
9.4.1. Key market trends, growth factors and opportunities
9.4.2. Market size and forecast, by Dose type
9.4.3. Market size and forecast, by Compounding Type
9.4.4. Market size and forecast, by Delivery method
9.4.5. Market size and forecast, by Sterility
9.4.6. Market size and forecast, by Technology
9.4.7. Market size and forecast, by country
9.4.7.1. Japan
9.4.7.1.1. Market size and forecast, by Dose type
9.4.7.1.2. Market size and forecast, by Compounding Type
9.4.7.1.3. Market size and forecast, by Delivery method
9.4.7.1.4. Market size and forecast, by Sterility
9.4.7.1.5. Market size and forecast, by Technology
9.4.7.2. China
9.4.7.2.1. Market size and forecast, by Dose type
9.4.7.2.2. Market size and forecast, by Compounding Type
9.4.7.2.3. Market size and forecast, by Delivery method
9.4.7.2.4. Market size and forecast, by Sterility
9.4.7.2.5. Market size and forecast, by Technology
9.4.7.3. India
9.4.7.3.1. Market size and forecast, by Dose type
9.4.7.3.2. Market size and forecast, by Compounding Type
9.4.7.3.3. Market size and forecast, by Delivery method
9.4.7.3.4. Market size and forecast, by Sterility
9.4.7.3.5. Market size and forecast, by Technology
9.4.7.4. Australia
9.4.7.4.1. Market size and forecast, by Dose type
9.4.7.4.2. Market size and forecast, by Compounding Type
9.4.7.4.3. Market size and forecast, by Delivery method
9.4.7.4.4. Market size and forecast, by Sterility
9.4.7.4.5. Market size and forecast, by Technology
9.4.7.5. South Korea
9.4.7.5.1. Market size and forecast, by Dose type
9.4.7.5.2. Market size and forecast, by Compounding Type
9.4.7.5.3. Market size and forecast, by Delivery method
9.4.7.5.4. Market size and forecast, by Sterility
9.4.7.5.5. Market size and forecast, by Technology
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Market size and forecast, by Dose type
9.4.7.6.2. Market size and forecast, by Compounding Type
9.4.7.6.3. Market size and forecast, by Delivery method
9.4.7.6.4. Market size and forecast, by Sterility
9.4.7.6.5. Market size and forecast, by Technology
9.5. LAMEA
9.5.1. Key market trends, growth factors and opportunities
9.5.2. Market size and forecast, by Dose type
9.5.3. Market size and forecast, by Compounding Type
9.5.4. Market size and forecast, by Delivery method
9.5.5. Market size and forecast, by Sterility
9.5.6. Market size and forecast, by Technology
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Market size and forecast, by Dose type
9.5.7.1.2. Market size and forecast, by Compounding Type
9.5.7.1.3. Market size and forecast, by Delivery method
9.5.7.1.4. Market size and forecast, by Sterility
9.5.7.1.5. Market size and forecast, by Technology
9.5.7.2. Saudi Arabia
9.5.7.2.1. Market size and forecast, by Dose type
9.5.7.2.2. Market size and forecast, by Compounding Type
9.5.7.2.3. Market size and forecast, by Delivery method
9.5.7.2.4. Market size and forecast, by Sterility
9.5.7.2.5. Market size and forecast, by Technology
9.5.7.3. South Africa
9.5.7.3.1. Market size and forecast, by Dose type
9.5.7.3.2. Market size and forecast, by Compounding Type
9.5.7.3.3. Market size and forecast, by Delivery method
9.5.7.3.4. Market size and forecast, by Sterility
9.5.7.3.5. Market size and forecast, by Technology
9.5.7.4. Rest of LAMEA
9.5.7.4.1. Market size and forecast, by Dose type
9.5.7.4.2. Market size and forecast, by Compounding Type
9.5.7.4.3. Market size and forecast, by Delivery method
9.5.7.4.4. Market size and forecast, by Sterility
9.5.7.4.5. Market size and forecast, by Technology
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product mapping of top 10 player
10.4. Competitive dashboard
10.5. Competitive heatmap
10.6. Top player positioning, 2024
CHAPTER 11: COMPANY PROFILES
11.1. ATS Corporation
11.1.1. Company overview
11.1.2. Key executives
11.1.3. Company snapshot
11.1.4. Operating business segments
11.1.5. Product portfolio
11.1.6. Business performance
11.2. Simplivia
11.2.1. Company overview
11.2.2. Key executives
11.2.3. Company snapshot
11.2.4. Operating business segments
11.2.5. Product portfolio
11.2.6. Key strategic moves and developments
11.3. Dedalus S.p.A.
11.3.1. Company overview
11.3.2. Key executives
11.3.3. Company snapshot
11.3.4. Operating business segments
11.3.5. Product portfolio
11.3.6. Key strategic moves and developments
11.4. EQUASHIELD
11.4.1. Company overview
11.4.2. Key executives
11.4.3. Company snapshot
11.4.4. Operating business segments
11.4.5. Product portfolio
11.4.6. Key strategic moves and developments
11.5. ARxIUM
11.5.1. Company overview
11.5.2. Key executives
11.5.3. Company snapshot
11.5.4. Operating business segments
11.5.5. Product portfolio
11.6. Grifols, S.A.
11.6.1. Company overview
11.6.2. Key executives
11.6.3. Company snapshot
11.6.4. Operating business segments
11.6.5. Product portfolio
11.6.6. Business performance
11.7. Biovalley Group S.p.A.
11.7.1. Company overview
11.7.2. Key executives
11.7.3. Company snapshot
11.7.4. Operating business segments
11.7.5. Product portfolio
11.8. Omnicell Inc.
11.8.1. Company overview
11.8.2. Key executives
11.8.3. Company snapshot
11.8.4. Operating business segments
11.8.5. Product portfolio
11.8.6. Business performance
11.8.7. Key strategic moves and developments
11.9. Kapsam Health Products
11.9.1. Company overview
11.9.2. Key executives
11.9.3. Company snapshot
11.9.4. Operating business segments
11.9.5. Product portfolio
11.10. Loccioni
11.10.1. Company overview
11.10.2. Key executives
11.10.3. Company snapshot
11.10.4. Operating business segments
11.10.5. Product portfolio